Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | PHASE3 | RECRUITING | 486 | — | — | Jun 11, 2024 | Mar 26, 2029 | Nov 25, 2025 | 6 | China, China +4 |
| Name | Type | Description |
|---|---|---|
| APG-2575(Lisaftoclax ) | DRUG | QD, oral administration, every 28 days for a dosing cycle. |
| Placebo | OTHER | QD, oral administration, every 28 days for a dosing cycle. |
| Azacitidine Injection | DRUG | QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle. |